Methods and products for biasing cellular development

ABSTRACT

Methods are described that bias cells, such as potent and multipotent stem cells, by transfection with a nucleic acid sequence, to differentiate to a desired end-stage cell or a cell having characteristics of a desired end-stage cell. In particular embodiments, human neural stem cells are transfected with vectors comprising genes in the homeobox family of transcription factor developmental control genes, and this results in a greater percentage of resultant transformed cells, or their progeny, differentiating into a desired end-stage cell or a cell having characteristics of a desired end-stage cell.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Ser. No. 60/621,483 filed Oct.22, 2004; and is a divisional application of U.S. application Ser. No.11/258,603, filed Oct. 24, 2005 now U.S. Pat. No. 8,080,420, which arehereby incorporated in their entirety.

FIELD OF INVENTION

The present invention is directed to methods and systems directed toaltering the differentiation of a cell, more particularly to biasing amultipotent stem cell by transfecting the cell with a nucleic acidsequence comprising a desired gene, the gene being expressed so that thecell, or its progeny, differentiate to a desired end-stage cell.

BACKGROUND

Proper cellular function and differentiation depends on intrinsicsignals and extracellular environmental cues. These signals and cuesvary over time and location in a developing organism (i.e., duringembryogenesis), and remain important in developing and differentiatingcells during post-natal growth and in a mature adult organism. Thus, ina general sense, the interplay of the dynamically changing set ofintracellular dynamics (such as manifested by intrinsic chemicalsignaling and control of gene expression) and environmental influences(such as signals from adjacent cells) determine cellular activity. Thecellular activity so determined is known to include cell migration, celldifferentiation, and the manner a cell interacts with surrounding cells.

The use of stem cells and stem-cell-like cells of various types for cellreplacement therapies, and for other cell-introduction-based therapies,is being actively pursued by a number of researchers. Embryonic stemscells from a blastocyst stage are frequently touted for theirpluripotency—that is, their ability to differentiate into all cell typesof the developing organism. Later-stage embryonic stem cells, andcertain cells from generative areas of an adult organism, are identifiedas more specialized, multipotent stem cells. These cells include cellsthat are able to give rise to a succession of a more limited subset ofmature end-stage differentiated cells of particular types or categories,such as hematopoietic, mesenchymal, or neuroectodermal end-stagedifferentiated cells. For example, a multipotent neural stem cell maygive rise to one or more neuron cell types (i.e., cholinergic neuron,dopaminergic neuron, GABAergic neurons), which includes their specificcell classes (i.e., a basket cell or a chandelier cell for GABAergicneurons), and to non-neuron glial cells, such as astrocytes anddendrocytes.

Further along the path of differentiation are cells derived frommultipotent stem cells. For example, derivatives of a localized,non-migrating neuroectodermal type stem cell may migrate but, comparedto their multipotent parent, have more limited abilities to self-renewand to differentiate (See Stem Cell Biology, Marshak, Gardner &Gottlieb, Cold Spring Harbor Laboratory Press, 2001, particularlyChapter 18, p. 407). Some of these cells are referred to aneuron-restricted precursors (“NRPs”), based on their ability, underappropriate conditions, to differentiate into neurons. There is evidencethat these NRPs have different subclasses, although this may reflectdifferent characteristics of localized multipotent stem cells (Stem CellBiology, Marshak et al., pp 418-419).

One advantage of use of mulitpotent and more committed cells furtheralong in differentiation, compared to pluripotent embryonic stem cells,is the reduced possibility that some cells introduced into an organismfrom such source will form a tumor (Stem Cell Biology, Marshak et al.,p. 407). However, a disadvantage of cells such as cell types developedfrom multipotent stem cells, for instance, embryonic progenitor cells,is that they are not amenable to ongoing cell culture. For instance,embryonic neural progenitor cells, which are able to differentiate intoneurons and astrocytes, are reported to survive only one to two monthsin a cell culture.

Generally, it is known in the art that the lack of certain factorscritical to differentiation will result in no or improperdifferentiation of a stem cell. Researchers also have demonstrated thatcertain factors may be added to a culture system comprising stem cells,such as embryonic stem cells, so that differentiation to a desired,stable end-stage differentiated cell proceeds. It also is known in theart to introduce and express a transcription factor gene, Nurr1, intoembryonic stem cells, and then process the cells through a five-stepdifferentiation method (Kim, Jong-Hoon et al., Dopamine Neurons Derivedfrom Embryonic Stem Cells Function in an Animal Model of Parkinson'sDisease, Nature, 418:50-56 (2002)), resulting in differentiated cellshaving features of dopaminergic cells. However, the starting cell forthis was an embryonic stem cell, and the differentiation process throughto a cell having the features of a dopaminergic neuron, requiressubstantial effort that includes the addition and control of endogenousfactors. In addition, because the starting cell is an early-stageembryonic stem cell having pluripotency, there is a relatively higherrisk that some cells implanted from this source will become tumerogenic.

Also, without being bound to a particular theory, it is believed that tothe extent a particular method of differentiation results in a greaterpercentage of cells that are dedicated or predetermined to differentiateto a desired functional cell type (i.e., a cholinergic neuron), thisreduces the chance of tumor formation after introduction of cellsderived from such method. As disclosed herein, embodiments of thepresent method that utilize multipotent stem cells as the startingmaterial provide an increased percentage of cells predisposed (i.e.,biased) to or differentiated to a desired cell type. This is believed toprovide for reduced risk of tumor formation equivalent to or superior tothe use of more differentiated cells such as NRPs.

There are many possible applications for methods, compositions, andsystems that provide for improved differentiation of stem cells to adesired functional, differentiated cell. For example, not to belimiting, millions of people suffer from deafness and balance defectscaused by damage to inner ear hair cells (IEHCs), the primary sensoryreceptor cells for the auditory and vestibular system after exposure toloud noises, antibiotics, or antitumor drugs. Since IEHCs rarelyregenerate in mammals, any damage to these organs is almostirreversible, precludes any recovery from hearing loss, and results inpotentially devastating consequences. Current therapies utilizingartificial cochlear implants or hearing aids may partially improve butnot sufficiently restore hearing. Therefore, cell therapy to replace thedamaged IEHC may be one of the most promising venues today. In the past,IEHC production from progenitor cells from the vestibular sensoryepithelium of the bullfrog {Cristobal, 1998 #28} and possible existenceof IEHC progenitors in mammalian cochlea sensory epithelia {Kojima, 2004#29} has been reported. However limited quantity of IEHC progenitorprevents clinical application of this type of cell to treat deafness.Thus novel technology to produce IEHCs from other cell sources isneeded.

While stem cells are known to be the building blocks responsible forproducing all of a body's cells, the specific differentiation processtowards to IEHC linage is not clear. Embryonic stem cells transplantedinto the inner ear of adult mice or embryonic chickens did notdifferentiate into IEHCs {Sakamoto, 2004 #19}. Neural stem cells (NSCs)grafted into the modiolus of cisplatin-treated cochleae of mice onlydifferentiated into glial or neuronal cells within the cochleae {Tamura,2004 #18}. In order to produce IEHCs from these stem cells, modificationor direction of the cell fate decision may be needed.

Another possible application for methods, compositions, and systems ofthe present invention is biasing Human Neural Stem Cells (“HNSCs”) todifferentiate to cholinergic neurons, or to cells having characteristicsof cholinergic neurons. Such biasing would provide for an improvedpercentage of such stem cells in a culture vessel to differentiate tothis desired end-stage nerve cell. Improvements to the percentage ofcells that are known to be biased to differentiate to this end-stageneuron cell, or to cells having characteristics of a cholinergic neuron,may lead to improvements both in research and treatment technologies fordiseases and conditions that involve degeneration or loss of function ofcholinergic neurons. Alzheimer's disease is one example of a maladyknown to be associated with degeneration of the long-projecting axons ofcholinergic neurons.

Thus, there is a need in the art to improve the compositions, methodsand systems that provide biased and/or differentiated cells from stemcells or stem-cell-like cells. More particularly, a need exists toobtain a higher percentage of desired cells from a pre-implantation cellculture, such as starting from multipotent stem cells and obtaining ahigher percentage of cells committed to differentiate to a specifiedtype of functional nerve cell, such as cholinergic neurons or inner earhair cells. The present invention addresses these needs.

BRIEF DESCRIPTION OF THE FIGURES

FIGS. 1-16 are appended hereto, are part of the specification, and aredescribed herein and/or on the figures themselves.

FIG. 3 Math 1 full length mRNA was amplified by RT-PCR and digested withApai, which cuts position 441 of Hath1ORF. Expecting fragment sizes are441 bp and 624 bp. M: 100 bp marker; 5, 6, without transfection(control); 7, 8: transfected with mammarian expression vector containingHath2.

FIG. 9: Phase contrast micrographs of LA-N2 cells. FIG. 9 a: LA-N2 cellsgrow in clusters as adherent fibroblasts-like cells, occasionally cellsextend short processes and form neuronal-like networks. FIG. 9 b: LA-N2cells treated with 10-6 μM retinoic acid.

FIG. 10: Lhx8 expression in the LA-N-2 and HNSCs cells. FIG. 10 a: Showsgene expression with RT-PCR analysis of LA-N-2 cells treated with ten μMRA showed an increased expression of Lhx8 (394 bp) and ChAT (splicevariants ˜600 and 400 bp, respectively, compared with non-treated cells.FIG. 10 b: represents RT-PCR analysis of Lhx8 expression in HNSCs 48hours post-transfection.

FIG. 11: In vitro differentiation of Lhx8-transfected HNSCs. HNXCstransfected with Lhx8 (a) in co-culture with LA-N-2 cells and serum-freeconditions differentiated mostly neurons with long extended processesafter 10-14 days (b-f).

FIG. 12: Differentiated HNSCs/Lhx8 in co-culture with LA-N-2 cells.Cells were double-immunofluorescence stained with (a) βIII-tubulin (red)and (b) ChAT (green), markers for colinergic neurons (c) twolocalization of βIII-tubulin and ChAT. Blue signal is a counter stainingfor nuclei by DAPI.

FIG. 13: Differentiated HNSCs/LHX8 in co-culture with law and 2 cells.Cells were double immunofluorescence stained with (a) βIII-tubulin(green) and (b) CHAT (red), markers for colinergic neurons (c)co-localization of βIII-tubulin and CHAT. (20× magnification) bluesignal is a counter staining for nuclei for DAPI. (d) insert fornon0-specific staining for c βIII-tubulin and CHAT, respectively.

FIG. 14 Differentiated HNSCs/Lhx8 in co-culture with LA-N-2 cells. A)βIII-tubulin (green) and b) ChAT (red), markers for cholinergic neurons,c) co-localization of βIII-tubulin & ChAT. Blue signal is a counterstaining for nuclei by DAPI (40× magnification).

FIG. 15 Differentiated non-transfected HNSCs in co-culture with LA-N-2cells. Cells were double-immunofluorescence stained with βIII-tubulin(green) and nuclei counter staining by DAPI (Blue). No Chat-positiveneurons were observed. (a-b) 10× and (c) 20× magnification,respectively.

FIG. 16 Differentiated non-transfected HNSCs in co-culture with LA-N-2cells. Cells were double-immunofluorescense stained with (a-b)βIII-tubulin (green) and (c) GFAP (red) markers for neurons andastrocytes, respectively. Blue signal is a counter staining for nucleiby DAPI.

DETAILED DESCRIPTION OF EMBODIMENTS OF THE INVENTION

In reviewing the detailed disclosure which follows, and thespecification more generally, it should be borne in mind that allpatents, patent applications, patent publications, technicalpublications, scientific publications, and other references referencedherein are hereby incorporated by reference in this application in orderto more fully describe the state of the art to which the presentinvention pertains.

Reference to particular buffers, media, reagents, cells, cultureconditions and the like, or to some subclass of same, is not intended tobe limiting, but should be read to include all such related materialsthat one of ordinary skill in the art would recognize as being ofinterest or value in the particular context in which that discussion ispresented. For example, it is often possible to substitute one buffersystem or culture medium for another, such that a different but knownway is used to achieve the same goals as those to which the use of asuggested method, material or composition is directed.

It is important to an understanding of the present invention to notethat all technical and scientific terms used herein, unless definedherein, are intended to have the same meaning as commonly understood byone of ordinary skill in the art. The techniques employed herein arealso those that are known to one of ordinary skill in the art, unlessstated otherwise. For purposes of more clearly facilitating anunderstanding the invention as disclosed and claimed herein, thefollowing definitions are provided.

DEFINITIONS

Stem cells are undifferentiated cells that exist in many tissues ofembryos and adult organisms. In embryos, blastocyst stem cells are thesource of cells that differentiate to form the specialized tissues andorgans of the developing fetus. In adults, specialized stem cells inindividual tissues are the source of new cells, replacing cells lostthrough cell death due to natural attrition, disease, or injury. Stemcells may be used as substrates for producing healthy tissue where adisease, disorder, or abnormal physical state has destroyed or damagednormal tissue.

Five defining characteristics of stem cells have been advanced (fromWeiss et al., 1996). That is, stems cells generally are recognized ashaving the ability to:

-   -   1. Proliferate: Stem cells are capable of dividing to produce        daughter cells.    -   2. Exhibit self-maintenance or renewal over the lifetime of the        organism: Stem cells are capable of reproducing by dividing        symmetrically or asymmetrically to produce new stem cells.        Symmetric division occurs when one stem cell divides into two        daughter stem cells. Asymmetric division occurs when one stem        cell forms one new stem cell and one progenitor cell. Symmetric        division is a source of renewal of stem cells. This permits stem        cells to maintain a consistent level of stem cells in an embryo        or adult mammal.    -   3. Generate large number of progeny: Stem cells may produce a        large number of progeny through the transient amplification of a        population of progenitor cells.    -   4. Retain their multilineage potential over time: The various        lines of stem cells collectively are the ultimate source of        differentiated tissue cells, so they retain their ability to        produce multiple types of progenitor cells, which in turn        develop into specialized tissue cells.    -   5. Generate new cells in response to injury or disease: This is        essential in tissues which have a high turnover rate or which        are more likely to be subject to injury or disease, such as the        epithelium or blood cells.

Thus, key features of stem cells include their capability ofself-renewal, and their capability to differentiate into a range ofend-stage differentiated tissue cells.

By “neural stem cell” (NSC) is meant a cell that (i) has the potentialof differentiating into at least two cell types selected from a neuron,an astrocyte, and an oligodendrocyte, and (ii) exhibits self-renewal,meaning that at a cell division, at least one of the two daughter cellswill also be a stem cell. Generally, the non-stem cell progeny of asingle NSC are capable of differentiating into neurons, astrocytes,Schwann cells, and oligodendrocytes. Hence, a stem cell such as a neuralstem cell is considered “multipotent” because its progeny have multipledifferentiative pathways. Under certain conditions an NSC also may havethe potential to differentiate as another non-neuronal cell type (e.g.,a skin cell, a hematopoietic cell, a smooth muscle cell, a cardiacmuscle cell, a skeletal muscle cell, a bone cell, a cartilage cell, apancreatic cell or an adipocyte).

By “Human Neural Stem Cell” (“HNSC”) is meant a neural stem cell ofhuman origin. A HNSC may be of fetal origin, or adult origin from aneural source, or may be derived from other cell sources, such as byde-differentiating a cell of mesenchymal origin. As to the latter, forexample see U.S. application serial number 2003/0219898, which isincorporated by reference, inter alia, specifically for this teaching.HNSCs of the invention are distinguished from natural HNSCs by theiradaptation for proliferation, migration and differentiation in mammalianhost tissue when introduced thereto.

By a “population of cells” is meant a collection of at least ten cells.A population may consist of at least twenty cells, or of at least onehundred cells, or of at least one thousand or even one million cells.Because the NSCs of the present invention exhibit a capacity forself-renewal, they can be expanded in culture to produce a collection oflarge numbers of cells.

By “potent cell” is meant a stem cell that has the capability todifferentiate into a number of different types of end-stage cell types,and to self-renew, and may include stem cells classified as pluripotent,multipotent, or cells more differentiated than multipotent (i.e., adedicated progenitor) under different stem cell classification schemes.

By “a presumptive end-stage cell” is meant a cell that has acquiredcharacteristics of a desired end-stage cell type, but which has not beenconclusively identified as being the desired end-stage cell. Apresumptive end-stage cell possesses at least two, and often more,morphological and/or molecular phenotypic properties of the desiredend-stage cell.

The practice of the present invention will employ, unless otherwiseindicated, conventional techniques of cell biology, cell culture,molecular biology, transgenic biology, microbiology, recombinant DNA,and immunology, which are within the skill of the art. Such techniquesare explained fully in the literature. See, for example, MolecularCloning A Laboratory Manual, 3^(rd) Ed., ed. by Sambrook, Fritsch andManiatis (Cold Spring Harbor Laboratory Press: 2001); DNA Cloning,Volumes I and II (D. N. Glover ed., 1985); Oligonucleotide Synthesis (M.J. Gait ed., 1984); Mullis et al., U.S. Pat. No. 4,683,195; Nucleic AcidHybridization (B. D. Hames & S. J. Higgins eds. 1984); Transcription AndTranslation (B. D. Hames & S. J. Higgins eds. 1984); Culture Of AnimalCells (R. I. Freshney, Alan R. Liss, Inc., 1987); Immobilized Cells AndEnzymes (IRL Press, 1986); B. Perbal, A Practical Guide To MolecularCloning (1984); the treatise, Methods In Enzymology (Academic Press,Inc., N.Y.); Gene Transfer Vectors For Mammalian Cells (J. H. Miller andM. P. Calos eds., 1987, Cold Spring Harbor Laboratory); Methods InEnzymology, Vols. 154 and 155 (Wu et al. eds.), Immunochemical MethodsIn Cell And Molecular Biology (Mayer and Walker, eds., Academic Press,London, 1987); Handbook Of Experimental Immunology, Volumes I-IV (D. M.Weir and C. C. Blackwell, eds., 1986); Manipulating the Mouse Embryo,(Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986).

U.S. Patent Application Nos. 2003/0219898, 2003/0148513, and2003/0139410 are incorporated by reference to the extent they are notinconsistent with the teachings herein. The first two of these patentapplications describe multiple uses of increased potency cells obtainedfrom the taught methods, and in particular, the implantation of stemcells for different therapeutic treatments of neurological trauma anddegenerative conditions. The third patent application is directed to theuse of certain compounds to stimulate proliferation and migration ofstem cells. Those skilled in the art will readily appreciate that thecells of the present invention could be obtained, or their effectivenessenhanced, by combining with the teachings of the aforementioned patentapplications, without undue experimentation.

The present invention is directed to compositions, methods and systemsthat provide for increased percentage of neural stem cells and othermultipotent or potent stem cells to become committed, or predisposed, todifferentiate to a desired end-stage differentiated nerve cell. Moreparticularly, the present invention utilizes the introduction into sucha stem cell of a nucleic acid sequence comprising a developmentalcontrol gene. A developmental control gene as used in the presentinvention may encode a transcription factor, cell-surface molecule, or asecreted signal molecule (See Fundamental Neuroscience, Zigmond, Bloom,Landis, Roberts and Squire, Academic Press, 1999, Chapter 15). Examplesbelow provide details of the introduction of three transcription factortype genes—Lhx8 and Gbx1 that improve differentiation of human neuralstem cells (HNSCs) to cells having characteristics of cholinergicneurons, and Hath1 that improves differentiation of HNSCs to cellshaving characteristics of inner ear hair cells (IEHCs). Theeffectiveness of these single-gene introductions to such cells isunexpected and surprising in view of the subtlety and complexity ofdifferentiation of multipotent stem cells to cells such as neural cellslike cholinergic nerve cells and inner ear hair cells. Other developmentcontrol genes having capability to achieve similar desired results aredisclosed.

The present invention advances the art by demonstrating the utility, inmultipotent stem cells, of introducing for expression a nucleic acidsequence that comprises a desired developmental control gene. Oneexample of such introducing is transfection by a vector comprising thenucleic acid sequence. After such introducing, the introduceddevelopmental control gene is expressed in the cell (or its progeny), atleast transiently. By so altering a multipotent stem cell, the presentinvention provides for more consistent differentiation to a desiredfunctional cell type, such as a cholinergeric nerve cell. In doing so,this is believed to reduce known risks of this type of celltransplantation, such as the risk of tumor growth upon implantation ofcells from pluripotent embryonic cell cultures.

Thus, in some embodiments the present invention is directed to biasing amultipotent cell such that the cell becomes programmed, or biased, todifferentiate into a desired cell type under appropriate externalconditions. This is done in some embodiments so that in apre-implantation cell culture a greater percentage of cells are eitherpre-disposed to differentiate to and/or do differentiate to a desiredcell type. More particularly, in certain embodiments of this biasing,the cell is transformed so it expresses a certain factor that biases thesame cells to differentiate to a desired cell type upon a laterimplantation to a particular tissue in a living organism. In suchembodiments, this improves a differentiation ratio so that a higherpercentage of cells introduced into a particular cell medium, a tissueculture, or a living organism in a particular location differentiateinto the end-stage differentiated cell type that is desired. Withoutbeing bound to a particular theory, this is believed to increase theprobability of success and overall effectiveness, and to decrease therisks associated with implantation of cells obtained from embryonic stemcells or embryonic-cell-like cells.

While not meant to be limiting as to the type of nucleic acid sequenceintroduced, examples herein utilize introduction to a cell of a nucleicacid sequence comprising a homeobox gene. This is a gene group thatincludes a number of known developmental control genes. A homeobox geneis a gene containing an approximately 180-base-pair segment (the“homeobox”) that encodes a protein domain involved in binding to (andthus regulating the expression of) DNA. The homeobox segment isremarkably similar in many genes with different functions. However,specific homeobox genes are known to operate at different stages, and indifferent tissue environments, to yield very different specific results.For example, in relatively early embryological development in thevertebrate embryo, expression of genes of the Hox family of homeoboxgenes appears to affect development of the brain based on position alongthe anterior/posterior axis. This is believed to control identity andphenotypic specializations of individual rhombomeres. (FundamentalNeuroscience, Zigmond et al., p. 435). Later in development, LIMhomeobox gene expression is associated with the projection pattern ofdeveloping primary motor neurons, and more generally, expression of aparticular combination of LIM homeobox genes appears to be related tomotor neuron subtype identity and to targeting specificity (FundamentalNeuroscience, Zigmond et al., p. 507). Also, some LIM homeobox genesappear to affect developmental progression, rather than fate, of motorneurons, which suggests a role of cell-to-cell signaling in the embryoto fully effectuate the differentiation in vivo (FundamentalNeuroscience, Zigmond et al., pp. 443-444). These highly specialized andvariable roles for homeobox genes in general, and for LIM familyhomeobox genes more particularly, demonstrate the subtle, specific, andhighly variable effects that these genes may have on cell and tissuedevelopment and differentiation.

Further with regard to function of homeobox genes, these genes encodetranscriptional regulators that play critical roles in a variety ofdevelopmental processes. Although the genetic and developmentalmechanisms that control the formation of forebrain cholinergic neuronsare just beginning to be elucidated, it is known that the vast majorityof forebrain cholinergic neurons derive from a region of the subcorticaltelencephalon that expresses the Nkx2-1 homeobox gene.

It has recently been reported that Nkx2-1 appears to specify thedevelopment of the basal telencephalon by positively regulatingtranscription factors such as the LIM-homeobox genes Lhx8 (also known asL3 or Lhx7) and Gbx1, which are associated with the development ofcholinergic neurons in the basal forebrain (Zhao et al., 2003; Asbreuket al., 2002, Waters et al., 2003).

In the spinal cord, IsL1, Lhx1, Lhx3 and Lhx4 have been shown to beimportant for the development of spinal cord cholinergic neurons (Pfaffet al., 1996; Sharma et al., 1998; Kania et al., 2000). Given that thespinal cord cholinergic neurons are reported to require multipleLIM-homeobox genes for their development, it is expected that Lhx8 isnot the only LIM-homeobox gene that is required in generatingtelencephalic cholinergic neurons. Other candidates are Lhx6 and IsL1,which are also expressed in the basal telencephalon (Marin et al.,2000). Also, it is suggested that Dlx1/2 and Mash, though not directlyregulating Lhx8, participate in controlling the number of cholinergicneurons that are formed in the telencephalon (Marin et al., 2000).

Thus, at a minimum, developmental control genes that may be used in thepresent invention to transfect cells to bias those cells (or theirprogeny) to differentiate to a desired end-stage cell type, here thatcell type being cholinergic neurons, include, but are not limited toLhx8, Gbx1, Lhx6, IsL1, Dlx1/2 and Mash.

The Human Neural Stem Cells (HNSCs), such as discussed in the examplesbelow, are obtained from cultures that were started from clones obtainedfrom human fetal brain tissue. One lineage was obtained by isolatingindividual cells from neurospheres of a fetal brain tissue sampleobtained from Cambrex, and ultimately identifying one multipotent stemcell for clonal propagation. A second lineage was obtained by isolatinga desired multipotent cell from a 9-week old fetal brain (Christopher L.Brannen and Kiminobu Sugaya, Neuroreport 11, 1123-8 (2000)). The HNSCsso obtained were maintained in serum-free medium, and have beendemonstrated to have the capability to differentiate into neurons andglial cells such as astrocytes and dendrocytes.

The following examples are provided to further disclose the genesis,operation, scope and uses of embodiments of the present invention. Theseexamples are meant to be instructive, and illustrative, and not to belimiting as to the scope of invention as claimed herein. These examplesare to be considered with the referred to drawings.

EXAMPLE 1

This example demonstrates that transfection of a human neural stem cellwith Hath1 results in the transfected cell (or its progeny)differentiating into a cell having markers of an inner ear hair cell(IEHC). Hath1 (in humans) and Math1 (in mice) are basic helix-loop-helixtranscription factors (and homologs of the Drosophila gene atonal) thatare expressed in inner ear sensory epithelia. Since embryonic Math1-nullmice failed to generate cochlear and vestibular hair cells, it appearsto be required for the generation of inner ear hair cells (Bermingham NA, Hassan B A, Price S D, Vollrath M A, Ben-Arie N, Eatock R A, Bellen HJ, Lysakowski A, Zoghbi H Y. 1999. Math1: An essential gene for thegeneration of inner ear hair cells. Science 284 (June 11): 1837-1841).Fate determination of mammalian IEHC is generally completed by birth.However, overexpression of Math1 in postnatal rat cochlear explantcultures resulted in production of extra hair cells from columnarepithelial cells located outside the sensory epithelium, which normallygive rise to inner sulcus cells. Math1 expression also facilitatedconversion of postnatal utricular supporting cells into hair cells(Zheng, G L, Gao Wq. 2000. Overexpression of Hath1 induces robustproduction of extra hair cells in postnatal rat inner ears. NatNeuroscience June; 3(6):580-6). In vivo, Math1 overexpression leads tothe appearance of immature hair cells in the organ of Corti and new haircells adjacent to the organ of Corti in the interdental cell, innersulcus, and Hensen cell regions, indicating nonsensory cells in themature cochlea retain the competence to generate new hair cells afterover expression of Math1 (Kawamoto K, Ishimoto S, Minoda R, Brough D E,Raphael Y. 2003. Math1 gene transfer generates new cochlear hair cellsin mature guinea pigs in vivo. J Neurosci June 1; 23(11):4395-400).Based on the above-summarized work, it was hypothesized that Hath1 maybe necessary, and sufficient as a single introduced gene for expressionin a multipotent neural stem cell, to positively affect differentiationto an IEHC, or to a cell having characteristics of an IEHC.

A Hath1 gene (SEQ ID NO:4) was amplified from the homo sapiens BAC cloneRP11-680J17 by PCR and then cloned it into a mammalian expressiondirectional cloning vector, pcDNAHismax TOPO TA (See FIG. 1; 6× His tagdisclosed as SEQ ID NO: 16). Upon the insertion of the Hath1 geneexpressible sequence into the directional cloning vector, theexpressible sequence was operatively linked to the CMV promoter, and wasalso positioned upstream (with regard to reading) of a polyadenylationtranscription termination site. The clone was confirmed by sequencing ofthe insert.

An established a non-serum HNSC culture system was utilized toinvestigate the differentiation of human neural stem cells (HNSCs)within a defined condition. (Christopher L. Brannen and Kiminobu Sugaya,Regeneration and Transplantation, 11:5, 1123-1128 (2000)). Theserum-free supplemented growth medium consisted of HAMS-F12 (Gibco, BRL,Burlington, ON), antibiotic/antimycotic mixture (1:100, Gibco), B27(1:50, Gibco), human recombinant FGF-2 and EGF (20 ng/ml each, R and DSystems, Minneapolis, Minn.), and heparin (5 ug/ml, Sigma, St. Louis,Mo.). Cells were maintained in 20 ml of this medium at 37° C. in a 5%CO₂ humidified incubation chamber.

The mammalian expression vector containing Hath1 gene was transfectedinto HNSCs by using the Neuroporter Kit (Gene Therapy Systems, Inc. SanDiego, Calif.) and Hath 1 gene expression was confirmed by RT-PCR. TheseHath1-transfected HNSCs were differentiated for 7 days by the depletionof mitotic factors (FGF-2, EGF) from the culture media. After thedifferentiation the cells were fixed for immunocytochemistry andElectron Microscopy.

The immunocytochemistry revealed the existence of cells expressingcalretinin, a hair cell marker, which were immunoreactive in thisculture. These calretinin immunopositive cells resembled morphology ofIEHC. The calretinin expression in the culture was also confirmed byWestern blot, which showed single band specific to calretinin molecularweight (29 kD). Further electron microscopy analysis of the cells alsoshowed a typical IEHC morphology. These results indicate that HNSCstransfected with a vector comprising a Hath1 gene differentiate intoIEHCs or into cells having characteristics of IEHCs. Comparisons withnon-transfected controls using Western blot and room temperature PCRshowed the presence of Hath1 protein and Hath1 mRNA in cells transfectedwith Hath1, but not in the controls.

Thus, embodiments of the present method provide for improved approachesto obtain IEHCs, or cell having characteristics of IEHCs, that arederived from HNSCs. Embodiments of the present invention provide ahigher percentage of a population of cells biased, or disposed, todifferentiate to IEHCs, or to cells having characteristics of IEHCs. TheHNSCs utilized in this example are readily and continuously cultured inserum-free culture medium. Without being limited, in vitro and in vivostudies and trials using cells so obtained from HNSCs may includeelectrophysiological assessment of the cells and investigation offunctional recovery after transplantation of the cells into the animalmodel of deafness. Positive findings in such pre-clinical studies mayadvance the art farther toward treatment of deafness via celltransplantation therapy using IEHCs produced from HNSCs.

Material and Methods

Hath 1 Transfection

The human Hath1 gene (SEQ ID NO:1) is amplified from the Homo sapiensBAC clone RP11-680J17 by PCR, using a forward primer(5′-TCCGATCCTGAGCGTCCGAGCCTT-3′, SEQ ID NO:14) and reverse primer(5′-GCTTCTGTCACCTTCCTAACTTGCC-3′, SEQ ID NO:15). The PCR amplificationis conducted in 20 μl volumes containing the BAC clone (100 ng), 1×amplification buffer, 1 μM of each primer, dNTP Mix (250 μM), and TaqDNA Polymerase (2.5 U). The PCR condition is 95° C. (30″), 59° C. (30″),72° C. (60″) for 35 cycles, with an initial denaturation of 95° C. (5′)and final elongation of 72° C. (15′). The PCR amplified fragment iscloned into a directional pcDNAHismax TOPO TA vector and the clone isconfirmed by sequencing of the insert.

The gene expression of Hath1 is assessed by RT-PCR with the followingcondition: 95° C. (60″), 56° C. (60″), 72° C. (60″) for 35 cycles, withan initial denaturation of 95° C. (5′) and final elongation of 72° C.(15′). The Hath1 gene is transfected into Human Neural Stem Cells(HNSCs) using the Neuroporter Kit. The Neuroporter kit utilizes alipid-based transfection system for the use with cultured primaryneurons, neuronal cell lines, and glial cells. DNA and Neuroporter areused in a ratio of 10 μg DNA/75 μl Neuroporter, utilizing 37.5 μl perwell in a 6-well plate and with total volumes of 1.5 mL growth media perwell. 10 μg of DNA is added to DNA Diluent to make a total volume of 125μl; this is incubated for 5′ at room temperature. 75 μl of theNeuroporter Reagent is added to serum-free media to make a final volumeof 125 μl. These solutions are incubated for 10 minutes to allowNeuroporter/DNA complexes to form, and then added directly to the HNSCsin a 6-well plate. One day later, the media is replaced with freshgrowth media; one day later, this is replaced with differentiation media(Basal Medium Eagle) to induce spontaneous differentiation. The cellsare cultured for 1-2 weeks in a basal differentiation medium containingEagle's salts and L-glutamine, which is not supplemented with FGF-2 orEGF, and is serum-free.

RT-PCR

TRIzol reagent is used to extract RNA for RT-PCR and protein for aWestern Blot. 6 μl of the template RNA is added to 1× Reaction Mix, 1 μMof each Hath1-specific primer, and 1 μl of the RT-Platinum® Taq Mix. Thetotal volume of the solution is 20 μl. The RT-PCR condition is 94° C.(15″), 59° C. (30″), 72° C. (60″) for 40 cycles, with an initialdenaturation of 55° C. (30′) and 94° C. (5′).

Immunocytochemistry

The cells are fixed with 4% paraformaldehyde for 30′ at roomtemperature, washed in phosphate-buffered saline (PBS, pH 7.2), thenblocked with 3% normal goat serum in PBS containing 0.05% Triton-X100for 1 hour. The cells are incubated with primary antibody calretininovernight at 4° C., with a dilution factor of (1:2000) in PBS containing0.05% Triton-X100.

Following PBST washing, the cells are incubated with secondary antibodybiotinylated anti-rabbit made in goat in PBS containing 0.05%Triton-X100 (PBST), with a dilution factor of 1:200. This incubationtakes 1 hour. The cells are washed with PBST, and incubated with ABCreagent for 1 hour. Following a PBS wash and staining with DAB for 5-8′,the cells are washed with PBS and distilled water, then stained withmethyl green (5′). The cells are washed with water, ethanol, and xylene,coverslipped with permount, and ready for viewing with microscopy.

Western Blot

A Western Blot is performed to assay protein expression. The protein isextracted with TRIzol reagent. 15 μl of the protein is loaded with thesize marker on a PVDF membrane and run at 200 V and 110 mA/gel for 50′.The transfer is run overnight at 15V, 170.0 mA at 4° C. The membrane isthen washed with PBST 2×10′ while rotating, and blocked with 3% milk for60′. This is washed 2×10′ with PBST and blocked with the primaryantibody calretinin (1:500) overnight at 4° C. After washing 3×5′ withPBST the membrane is incubated with the secondary antibody (1:2000) andshaken for 1 hour. For detection, 7.5 mL of ECL solution is warmed toroom temperature and 187.5 μl of solution B is added to solution A. 7.5mL is added to the membrane at RT for 5′. The membrane is then placed inan x-ray film cassette and exposed as needed for chemilumescentdetection.

Electron Microscopy

Cells were fixed with 3% glutaraldehyde with cacodyate buffer 0.1M, anddehydrated with a series of alcohols beginning with 50% up to 100%absolute ethanol followed by hexamethyldislazne (HMDS). The culturedcells were allowed to air-dry at room temperature. The specimens wereattached to aluminum stubs using double sided carbon coated tape,sputter-coated with Platinum and palladium using the Cressington 208 HRHigh Resolution Coater. Samples were viewed with a Jeol 6320F FieldEmission Microscope (high resolution images) and recorded with a digitalcamera. Samples were also viewed with the Hitachi Variable pressuremicroscope in V-P mode (variable pressure mode) and digitals werecaptured.

Results

A non-serum HNSC culture system was utilized (Christopher L. Brannen andKiminobu Sugaya, Regeneration and Transplantation, 11:5, 1123-1128(2000)). This culture system provides for the differentiation andexpansion of HNSCs in vitro in the absence of serum. This systemprovides for the observation of differentiation of HNSCs within adefined condition. These HNSCs have been cultured in a medium consistingof DMEM/F12, antibiotic-antimycotic mixture (1:100), B-27 supplement(1:50), human recombinant FGF-2 and EGF (20 ng/ml each), and heparin (5μg/ml). These cells have been maintained at 37° C. in a 5% CO2humidified incubation chamber for more than 3 years in the lab. Thesecells are CD133- (a stem cell marker, which is known to be expressed instem cells) positive, and GFAP- and βIII-tubulin-negative beforedifferentiation. Upon differentiation, various differentiated cellstypically express glial fibrillary acidic protein (GFAP), orβIII-tubulin, which are glial and neuronal markers, respectively.

Preferential differentiation of HNSCs into IEHCs can be induced in vitroby the transfection of Hath1. The human Hath1 gene was amplified fromthe Homo sapiens BAC clone RP11-680J17 by PCR and cloned into adirectional pcDNAHismax TOPO TA vector. This was confirmed by sequencingof the insert. After confirming expression of the gene by RT-PCR, theNeuroporter kit was utilized to tranfect HNSCs. These HNSCs were knownto be viable and capable of differentiation, aggregrating inneurospheres when multipotent. Once they began the process ofdifferentiation, they left their neurospheres. After allowing 7 days fordifferentiation, these cells were either stained for hair cell specificmarkers or assayed for protein expression. Via immunocytochemistry, thehair cell marker calretinin was identified on certain cells (FIG. 2).Via RT-PCR, the expression of this protein XX clarify which figure orprotein? was also verified (FIG. 3).

The presence of the actual protein calretinin on the cell surface wasdetermined via Western Blot. Seven days for differentiation was allowedbefore any analysis of the cells. Protein was isolated from the cellsand calretinin was identified in the cell isolate (FIG. 4).

Using Transmission Electron Microscopy, cells transfected with Hath1 andgrown to allow for differentiation were visualized. A subset of thecells exhibited distinct hair-like projections. These were the actualhairs from the transfected HNSCs that differentiated into cells havingthis characteristic feature of IEHCs (FIGS. 5 and 6).

Discussion

In order to replace damaged IEHCs, a renewable source must be created.The HNSCs cultured in serum-free medium were shown to have the abilityto become transfected by Hath1 and then differentiate in vitro intoIEHCs, or cells having characteristics of IEHCs. In the present example,transfection with and expression of Hath1 appears to be an essentialstep in the genesis from HNSCs to IEHCs, or cells having characteristicsof IEHCs.

Before transfection, HNSCs do not express Hath1. Following transfectionwith the Neuroporter Kit, they express this gene in their DNA asverified by RT-PCR. They also produce the hair cell specific markercalretinin as verified by immuncytochemistry and Western Blot.Furthermore, actual hairs from the transfected cells can be visualizedthrough electron microscopy. Thus, characteristics of IEHCs are shown bythese data, and it appears that these cells either are end-stage IEHCsor are presumptive IEHC cells in that they have at least twocharacteristics of IEHCs.

Cells expressing IEHC markers and differentiating into cells withhairlike extremities have been generated in this example. These methods,and the cells produced by the methods of the present invention, as shownin this example, advance the art of differentiating multipotent stemcells toward obtaining end-stage neuron-type cells.

EXAMPLE 2 Introduction

A cholinergic deficit is one of the primary features of Alzheimer'sdisease (AD), where there is a marked degeneration of long-projectingaxons of cholinergic neurons in the basal forebrain and target areas inthe hippocampus and cerebral cortex. Recent progress in stem celltechnologies suggests the probability of using neuroreplacementstrategies in AD therapy, although several hurdles are implicated: i) isit possible to generate large numbers of cholinergic neurons from stemcells; and ii) can long-projecting cholinergic neurons be replaced?Toward improving the ability to conduct research in the area of cellimplantation and replacement therapies, and toward achieving desiredresults in later-developed therapies, embodiments of the presentinvention are directed to bias human neural stem cells (HNSCs) todifferentiate to cells having characteristics of cholinergic neuronsthrough genetic manipulation of endogenous neural precursors in situ.

The LIM-homeobox gene Lhx8 has been reported to be crucial for theproper development of basal forebrain cholinergic neurons in mouse (Zhaoet al., 2003; Mori et al., 2004). Lhx8 is expressed in progenitor andpostmitotic cells, suggesting that it may have an important role inspecification of neural precursor cells and maintenance of phenotype indifferentiating and mature neurons. Furthermore, previous studies usingthe human neuroblastoma cell line, LA-N-2, have demonstrated thattreatment with retinoic acid (RA) further enhances cholinergiccharacteristics of these cells, thus providing a good in vitro model ofcholinergic neurons (Crosland, 1996).

The present example utilizes an in vitro assay cell co-culture modelwith plated RA-differentiated LA-N-2 cells and membrane insertscontaining Lhx8-transfected HNSCs, to assess whether theLhx8-transfected HNSCs adopt a cholinergic neuronal fate. The rationalebehind this co-culture model is that HNSCs are influenced by intrinsicas well as extracellular factors in the microenvironment and therefore,able to respond by differentiating into specific cell types according tothe environmental cues to which they are exposed. Culture ofRA-differentiated LA-N-2 in basal media under a serum-free condition,results in the release of factors to the Lhx8-transfected HNSCs inco-culture. It should be noted that there is no cell-to-cell contact inthis co-culture system. Thus it is reasonable to assume that anymodification of the cell fate of the genetically modified HNSCs by thecholinergic-differentiated LA-N-2 cells would come from membranepermeable endogenous factor(s) released from thecholinergic-differentiated LA-N-2 cells.

Materials & Method

HNSCs culture: Human NSCs were originally purchased from BioWhittaker,Walkersville, Md. These cells have been expanded and passaged in aserum-free culture medium containing bFGF and EGF in our laboratory forover three years (Brannen & Sugaya, 2000). The HNSCs were cultured at adensity of 50 spheres in 75 cm² culture flasks (Corning, Cambridge,Mass.) in 20 ml of a serum-free supplemented growth medium consisting ofHAMS-F12 (Gibco, BRL, Burlington, ON), antibiotic-antimycotic mixture(1:100, Gibco), B27 (1:50, Gibco), human recombinant FGF-2 and EGF (20ng/ml each, R&D Systems, Minneapolis, Minn.) and heparin (5 μg/ml,Sigma, St. Louis, Mo.) incubated at 37° C. in a 5% CO² humidifiedincubation chamber (Fisher, Pittsburg, Pa.). To facilitate optimalgrowth conditions, HNSCs were sectioned into quarters every 2 weeks andfed by replacing 50% of the medium every 4-5 days.

LA-N-2 human neuroblastoma culture: LA-N-2 cells were obtained from Dr.Jan Blusztajn (Boston University, Mass.). The cells were cultured inLeibovitz L-15 medium (Gibco, BRL, Burlington, ON) containing 10% fetalcalf serum and antibiotic-antimyotic mixture (Gibco) in a humidifiedincubator at 37° C. without CO2. The medium was replaced every 3 days.For treatment with retinoic acid (RA), the cells were sub-plated at adensity of 0.5-1×10⁶ cells/plate using 0.25% trypsin/1 mM EDTA (Gibco,BRL) and allowed to attach overnight. A fresh stock of 4 mM all-transretinoic acid RA (Sigma, St. Louis, Mo.) was prepared in 100% ethanolunder amber lighting. RA solution was diluted into culture media (finalconcentration. 10⁻⁶M) and we replaced the media in the cells with theRA-containing media. The media was changed every 48 h during thedifferentiation of the cells, which was complete after 7-14 days.

Lhx8 subcloning: The mouse cDNA clone for Lhx8 (SEQ ID NO: 7, a kindgift from Dr Westphal, NIH, Bethesda, Md.) was inserted into the EcoR1site of the pcDNA 3.1/Zeo mammalian expression vector (Invitrogen).Insertion was subsequently confirmed by restriction digestion andsequence analysis. This mouse Lhx8 (SEQ ID NO: 7) has high homology tothe human sequence (70-80%).

Transfection: HNSCs were placed in 6-well poly-lysine coated plates andtransfected with 4 μg pcDNA 3.1/Lhx8 plasmid using the Neuroportertransfection system (Gene Therapy Systems, see description in Example1). Upon the insertion of the Lhx8 gene expressible sequence into thedirectional cloning vector, the expressible sequence was operativelylinked to the CMV promoter, and was also positioned upstream (withregard to reading) of a polyadenylation transcription termination site.Lhx8 expression was confirmed after 48 hrs by RT-PCR using primersdesigned from the gene cDNA sequence; 5′TGCTGGCATGTCCGCTGTCT′ 3 (SEQ IDNO: 12, upper primer) and 5′CTGGCTTTGGATGATTGACG′3 (SEQ ID NO: 13, lowerprimer). To initiate differentiation, HNSCs were placed in serum-freebasal medium, and allowed to differentiate for 10-15 days in culture.

Co-cultures of transfected HNSCs and RA-treated LA-N-2 cells: HNSCs(˜5×10⁴) transfected with pcDNA 3.1/Lhx8 and non-transfected HNSCs(controls) were transferred into cell culture inserts with anappropriate pore size and suspended in basal media (in the absence ofFGF-2 and EGF and without the addition of other extrinsicdifferentiation factors) over differentiated LA-N-2 cells plated in6-well plates. For immunocytochemical analyses of HNSCs, the cultureinsert was removed after 10-20 days of co-culture and the HNSCs werefixed with 4% paraformaldehyde overnight at 4° C. Also, transfectedHNSCs were cultured without the presence of differentiated LA-N-2 cellsto assess the need for and effectiveness of the co-culturing.

Immunocytochemistry:

Following fixation, HNSCs were briefly washed 3×5 min in Phosphatebuffered saline (PBS), then blocked with 3% normal donkey serum in PBScontaining 0.05% Tween 20 (PBS-T) and incubated with goat IgG polyclonalanti-human ChAT (1:500, Chemicon), mouseIgG2b monoclonal anti-humanβIII-tubulin (1:1000, Sigma) or rabbit anti-human glial filament protein(GFAP) (1:1000, Sigma) overnight at 4° C. The corresponding secondaryantibodies (donkey anti-goat, donkey anti-mouse, and donkey anti-rabbit,respectively) conjugated to rhodamine or FITC (Jackson IR Laboratories,Inc.) were added for a 2 hr incubation at RT in the dark. Cells werethen washed with PBS (3×5 min) and mounted with Vectashield with DAPI(Vector Laboratories, Calif.) for fluorescent microscopic observation.LA-N-2 cells were similarly treated to prepare for microscopicobservations.

Results

LA-N-2 cells treated with RA expressed Lhx8, βIII-tubulin, and ChAT.This is demonstrated in FIGS. 7A-D. FIG. 7A shows LA-N-2 cells stainedred indicating the presence of βIII-tubulin. FIG. 7B shows LA-N-2 cellsstained green indicating the presence of ChAT. FIG. 7C shows LA-N-2cells stained green indicating the presence of NGF (blue stainindicating counter-staining for nuclei by DAPI). FIG. 7D (insert) showsnon-specific staining for ChAT.

In vitro, HNSCs expressing the LIM homeobox gene, Lhx8, differentiatedinto mainly βIII-tubulin and ChAT-positive cells, in co-culture withLA-N-2 cholinergic cells. For the transfected HNSCs cultured without thepresence of differentiated LA-N-2 cells, there was no significantdifference from the non-transfected HNSCs with regard to the number ofcells differentiating to cells having characteristics of cholingericcells. This demonstrated the need under these experimental conditionsfor the differentiated LA-N-2 cells (and the factors released by them).

Non-transfected HNSCs differentiated into mainly βIII-tubulin and GFAPpositive cells in co-culture with LA-N-2 cholinergic cells.

With regard to percentage differences between non-transfected cells andtransfected cells, in one trial less than two percent of non-transfectedcells, and over 40 percent of transfected cells, were observed at theend of the trial to have characteristics of cholinergic neurons.

CONCLUSIONS AND COMMENTS

Expression of the LIM-homeobox gene Lhx8 triggers HNSCs to adopt acholinergic neural lineage. Cells having the noted characteristics ofcholinergic neurons either are cholinergic neurons or presumptivecholinergic neurons in that they have at least two characteristics ofcholinergic neurons.

LA-N-2 cells in co-culture with HNSCs expressing Lhx8, suggest that themicroenvironment is also important for the differentiation and survivalof cholinergic neurons.

The present invention may provide utility by biasing human neural stemcells through genetically manipulation so that the cells so manipulatedmay be used in research, including as cells transplantable, such as inexperiments, and therapies, including regarding replacing damagedcholinergic neurons.

As to the efficiency of biasing to a desired cell type, and to observingcells having characteristics of a desired end-stage cell type, withoutbeing bound to a particular theory, it is believed that the factors thatincrease the efficiency of biasing by transfection include: 1) inherentproperties of the cell to be transfected; 2) inherent efficiency of theselected vector or method of transfection; 3) relative percentage ofcells in which the introduced nucleic acid sequence enters the nucleuscompared to remains in the cytoplasm; and 4) number of copies of thenucleic acid sequence that are available for expression in the cell.Methods of transfection are well-known in the art, and the use andmodification of known approaches to transfection of a cell with anucleic acid sequence to be expressed therein to improve the percentageof biasing are within the scope of the present invention.

Thus, it is appreciated that in some embodiments of the presentinvention, a multipotent stem cell is transfected with a desireddevelopmental control gene, and the expression of the gene during invitro culture biases the differentiation of that cell to a desiredend-stage differentiated cell. In other embodiments, the multipotentstem cell may be transfected in vivo with a developmental control genewhose expression biases transfected cells to differentiate into adesired end-stage cell. In any of such embodiments, accessory cells mayprovide factors that are needed for, or that assist with, thedifferentiation of the transfected cell. These accessory cells, such asthe co-cultured LA-N-2 cells in the above example, need not be incontact with the transfected cells, demonstrating here that the factorsare membrane permeable. These factors may include the same factor thatis expressed by the transfected gene, or may be other factors known inthe art or later determined to be useful in achieving a desireddifferentiation.

Also, it is appreciated that multipotent stem cells may be culturedwithout an accessory cell, and may receive factors by direct addition offactors to the culture medium, or such factors may be released by cellsat a site of implantation, or may be added to a site of implantation.

EXAMPLE 3

Using the same vector formation and transfection methods as in Example2, the Human Lxh8 gene (SEQ ID NO: 6) is transfected into HNSCs.Transfected NHSC cells are cultured in a first treatment that includesLA-N-2 cells that are treated with RA and that express both Lhx8 andChAT. A co-culture control comprises NHSCs that are not transfected butthat are in the same culture vessel as LA-N-2 that are treated with RAand that express both Lhx8 and ChAT. For the first treatment and theco-culture control, HNSC cells are placed in cell culture inserts withan appropriate pore size and suspended in basal media (in the absence ofFGF-2 and EGF and without the addition of other extrinsicdifferentiation factors) over differentiated LA-N-2 cells plated in6-well plates.

Immunochemistry follows the same procedure as in Example 2 above.

Results indicate that HNSCs transfected with the Human Lxh8 gene (SEQ IDNO: 6) also are predisposed, or biased, to differentiate into cells thathave characteristics of cholinergic neurons. Observable results includecells that are positive for βIII-tubulin and ChAT.

EXAMPLE 4

An additional development control gene, Gbx1 sequence (SEQ ID NO: 9), istransfected into HNSCs and is evaluated as to its capacity to bias HNSCsto differentiate to cholingeric cells, or to cells havingcharacteristics of cholinergic cells. The Gbx1 cDNA sequence (SEQ ID NO:9) is inserted into the enhanced green fluorescent protein (EGFP) vectorpEGFP-C1 ((BDBiosciences Clontech) at the EcoR1 site within the vector'smultiple cloning site, which is 3′ of a CMV promoter and the EGFP gene(See FIG. 8; sequence disclosed as SEQ ID NO: 17). Further, in that aquestion remains as to whether the percentage of biasing is relateddirectly to the percentage of transfection of cells in population ofcells exposed to a transfecting vector, the human Lhx8 cDNA (SEQ IDNO:6) independently also is inserted into a second pEGFP-C1 vector. Thisallows for visualization of both vectors, each bearing an expressiblesequence for a different developmental control gene, in cells inrespective cell populations into which these vectors are transfected.

Culture methods of the HNSCs into which the Gbx1 and the Lhx8 genes aretransfected are as described above in Example 2.

This experiment provides an estimate of the ratio of HNSCs that becomecholinergic neurons based on percent transfected of the population.Compared to non-transfected control HNSCs, the transfected cells havecharacteristics of the desired end-stage differentiated cell type, thatis, a cholinergic neuron.

This demonstrates that a number of development control genes,particularly transcription factor genes, may be introduced into a HNSCto bias that cell (or its progeny) to differentiate to a cell having thecharacteristics of a desired end-stage differentiated neural cell type.

EXAMPLE 5

Cell sorting technology is combined with the above-described embodimentsof the present invention, particularly the vectors of Example 4, toimprove the yield and selection of desired cells having the bias todifferentiate to a desired end-stage cell (or having already sodifferentiated). For example, not to be limiting, the introduction ofgenetic marking such as described above, using EFGP, and the use ofFluorescent Activated Cell Sorter (FACS) techniques is utilized to sortand select cells that have been transfected with the desireddevelopmental control gene (which is linked to a marker on the vector).The FACS technology is well known in the art (See, for example, U.S.patent application number 2002/0127715 A1.)

Using FACS, HNSCs that are transfected with a vector bearing both EFGPand either Gbx1 or Lhx8 are sorted and thereby concentrated. This addsto the utility and effectiveness of the biasing by reducing the numberand percentage of cells that are not transfected.

The above examples utilize specific sequences of genes incorporated intorespective vectors and introduced into HNSCs. However, the presentinvention is not meant to be limited to the specifics of these examples.First, in addition to Math1, Hath1, Lxh8 and Gbx1, other developmentalcontrol genes of interest include Lhx6, IsL1, Dlx1/2 and Mash. Examplesof cDNA sequences, and corresponding translated polypeptide and proteinsequences, of these and other developmental control genes are readilyobtainable from the GenBank online database (Seencbi.nlm.nih.gov/entrez/query.fcgi.), and these are hereby incorporatedby reference for that purpose.

Also, as to the nucleic acid sequences comprising the genes of interest,specific sequences of which are provided in the above examples and inthe above paragraph, it is appreciated that substantial variation mayexist in a nucleic acid sequence for a gene, yet a polypeptide orprotein may nonetheless be produced in a cell from one of a number ofsuch variant nucleic acid sequences, wherein such polypeptide or proteinhas a desired effect on the cell comparable to a polypeptide or proteinproduced from one of the nucleic acid sequences specified in the aboveexamples. That is, variations may exist in a nucleic acid sequence for agene yet the variations nonetheless function effectively whensubstituted for a nucleic acid sequence of a specified gene.

Accordingly, embodiments of the present invention also include and/oremploy nucleic acid sequences that hybridize under stringenthybridization conditions (as defined herein) to all or a portion of anucleic acid sequence represented by any of the SEQ ID Nos. 1-13, ortheir complements, or to sequences for IsL1, Dlx1/2, Mash, or theircomplements. The hybridizing portion of the hybridizing nucleic acidsequences is typically at least 15 (e.g., 20, 25, 30, or 50) nucleicacids in length. The hybridizing portion of the hybridizing nucleic acidsequence is at least 80%, e.g., at least 95%, or at least 98%, identicalto the sequence of a portion or all of a nucleic acid sequence encodingone of genes identified by the noted Sequence ID numbers, or one oftheir complements. Hybridizing nucleic acids of the type describedherein can be used, for example, as a cloning probe, a primer (e.g., aPCR primer), or a diagnostic probe, as well as for a gene transfectedinto a cell as described in the examples above.

Hybridization of the oligonucleic acid probe to a nucleic acid sampletypically is performed under stringent conditions. Nucleic acid duplexor hybrid stability is expressed as the melting temperature or Tm, whichis the temperature at which a probe dissociates from a target DNA. Thismelting temperature is used to define the required stringencyconditions. If sequences are to be identified that are related andsubstantially identical to the probe, rather than identical, then it isuseful to first establish the lowest temperature at which onlyhomologous hybridization occurs with a particular concentration of salt(e.g., SSC or SSPE).

Then, assuming that 1% mismatching results in a 1° C. decrease in theTm, the temperature of the final wash in the hybridization reaction isreduced accordingly (for example, if sequences having >95% identity withthe probe are sought, the final wash temperature is decreased by 5° C.).In practice, the change in Tm can be between 0.5° C. and 1.5° C. per 1%mismatch. Stringent conditions involve hybridizing at 68° C. in5×SSC/5×Denhardt's solution/1.0% SDS, and washing in 0.2×SSC/0.1% SDS atroom temperature. Moderately stringent conditions include washing in3×SSC at 42° C. The parameters of salt concentration and temperature canbe varied to achieve the optimal level of identity between the probe andthe target nucleic acid. Additional guidance regarding such conditionsis readily available in the art, for example, by Sambrook et al., 1989,Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, N.Y.;and Ausubel et al. (eds), 1995, Current Protocols in Molecular Biology,(John Wiley & Sons, N.Y.) at Unit 2.10.

The above-specified sequences are not meant to be limiting. For example,provided herein are additional identified sequences for Math1 (SEQ IDNos:2 and 3), and Hath1 (SEQ ID NO:5). Numerous other similar sequencesare known and searchable at GenBank. Also, the methods and compositionsdisclosed and claimed herein for other sequences may be practiced withGbx1 (SEQ ID NO:9) and sequences similar to it.

Further, the sequences for introduced genes and polypeptides or proteinsexpressed by them may also be defined in terms of homology to one of thesequences provided in the above examples and discussion. In the contextof the present application, a nucleic acid sequence is “homologous” withthe sequence according to the invention if at least 70%, preferably atleast 80%, most preferably at least 90% of its base composition and basesequence corresponds to the sequence specified according to theinvention. According to the invention, a “homologous protein” is to beunderstood to comprise proteins which contain an amino acid sequence atleast 70% of which, preferably at least 80% of which, most preferably atleast 90% of which, corresponds to the amino acid sequence disclosed in(Gish and States, 1993); wherein corresponds is to be understood to meanthat the corresponding amino acids are either identical or are mutuallyhomologous amino acids. The expression “homologous amino acids” denotesthose which have corresponding properties, particularly with regard totheir charge, hydrophobic character, steric properties, etc. Thus, aprotein may be from 70% up to less than 100% homologous to any one ofthe proteins expressed by one of the disclosed introduced genes.

Homology, sequence similarity or sequence identity of nucleic acid oramino acid sequences may be determined conventionally by using knownsoftware or computer programs such as the BestFit or Gap pairwisecomparison programs (GCG Wisconsin Package, Genetics Computer Group, 575Science Drive, Madison, Wis. 53711). BestFit uses the local homologyalgorithm of Smith and Waterman, Advances in Applied Mathematics 2:482-489 (1981), to find the best segment of identity or similaritybetween two sequences. Gap performs global alignments: all of onesequence with all of another similar sequence using the method ofNeedleman and Wunsch, J. Mol. Biol. 48:443-453 (1970). When using asequence alignment program such as BestFit, to determine the degree ofsequence homology, similarity or identity, the default setting may beused, or an appropriate scoring matrix may be selected to optimizeidentity, similarity or homology scores. Similarly, when using a programsuch as BestFit to determine sequence identity, similarity or homologybetween two different amino acid sequences, the default settings may beused, or an appropriate scoring matrix, such as blosum45 or blosum80,may be selected to optimize identity, similarity or homology scores.

Alternatively, as used herein, “percent homology” of two amino acidsequences or of two nucleic acids is determined using the algorithm ofKarlin and Altschul (Proc. Natl. Acad. Sci. USA 87:2264-2268, 1990),modified as in Karlin and Altschul (Proc. Natl. Acad. Sci. USA90:5873-5877, 1993). Such an algorithm is incorporated into the NBLASTand XBLAST programs of Altschul et al. (J. Mol. Biol. 215:403-410,1990). BLAST nucleic acid searches are performed with the NBLASTprogram, score=100, wordlength=12, to obtain nucleic acid sequenceshomologous to a nucleic acid molecule of the invention. BLAST proteinsearches are performed with the XBLAST program, score=50, wordlength=3,to obtain amino acid sequences homologous to a reference polypeptide. Toobtain gapped alignments for comparison purposes, Gapped BLAST isutilized as described in Altschul et al. (Nucleic Acids Res.25:3389-3402, 1997). When utilizing BLAST and Gapped BLAST programs, thedefault parameters of the respective programs (e.g., XBLAST and NBLAST)are used. See ncbi.nlm.nih.gov.

Further, in addition to the homology, as indicated in certain claims(i.e., for some embodiments), is a requirement that the homologous orhybridizable nucleic acid sequence or polypeptide or protein functionsanalogously to the specified sequence of which it is homologous or withwhich it is hybridizable. That is, the homologous or hybridizablevariant functions to achieve the same result, i.e., to increase theprobability of a transfected cell, or the percentage of a number ofcells, that are biased to differentiate to a cell, or cells,respectively, having characteristics of a desired end-stagedifferentiated cell.

While the transfection into HNSCs in the above examples uses theNeuroporter approach (Gene Therapy Systems, Inc. San Diego, Calif.), itis appreciated that any known or later-developed method of introductionof a nucleic acid sequence may be employed in the methods and systems,and to produce the compositions, of the present invention. For example,and not to be limiting, introduction of a nucleic acid sequence may beeffectuated by stable or transient transfection, lipofection by methodsother than Neuroporter, calcium phosphate treatment, electroporation,infection with a recombinant viral vector, and the use of vectorscomprising a plasmid construct. Generally and collectively, thesemethods are considered to be included in the term “means to transfect,”in the term “step for transfecting.”Also, the use of the particularpromoter and polyadenylation transcription termination site are notmeant to be limiting, as many promoter and transcription terminationsites are known and used routinely in the art.

As to the use of different means to transfect, and in view of the abovediscussion of the relative percentage of cells biased to cells havingcharacteristics of a desired end-stage cell type, it is appreciated thattypes of transfection, cells that are transfected, and other factors,including post transfection conditions, affect the percentage of cellsultimately biased. In view of these factors, and considering theimportance of the specific developmental control genes that areintroduced to a cell in certain embodiments of the present invention, insome embodiments the percentage of transfected cells biased exceeds 40percent, in other embodiments the percentage of transfected cells biasedexceeds 50 percent, in other embodiments the percentage of transfectedcells biased exceeds 65 percent, and in other embodiments the percentageof transfected cells biased exceeds 70 percent. However, it also isappreciated that determination of the percentage of cells that are infact transfected in a given container of cells may be difficult toassess, the performance of the present invention in certain embodimentsmay be expressed in an alternative manner. That is, in some embodimentsof the present invention in which a number of cells has been exposed toa selected method or means of transfection for the purpose ofintroducing a desired developmental control gene (such as Lhx8), thepercentage of total cells that are biased to a desired end-stage celltype, or to a cell having characteristics of a desired end-stage celltype, is at least 35 percent, in other embodiments such percentage oftotal cells exceeds 50 percent, and in other embodiments such percentageof total cells exceeds 70 percent.

Further, it is appreciated that embodiments of the present invention aredescribed as follows:

-   -   1. A neural stem cell, including a human neural stem cell,        comprising an introduced nucleic acid sequence having an        expressible developmental control gene, the expression of said        gene being effective to increase the probability of        differentiation of said cell to a desired neural cell type.    -   2. A neural stem cell, including a human neural stem cell,        comprising an introduced nucleic acid sequence having an        expressible developmental control gene, the expression of said        gene being effective to increase the probability of        differentiation of said cell to a cell having characteristics of        a cholinergic neuron.    -   3. A neural stem cell, including a human neural stem cell,        comprising an introduced nucleic acid sequence having an        expressible developmental control gene, the expression of said        gene being effective to increase the probability of        differentiation of said cell to a cell having characteristics of        an inner ear hair cell.    -   4. A neural stem cell, including a human neural stem cell,        comprising an introduced nucleic acid sequence having an        expressible developmental control gene, the expression of said        gene being effective to increase the probability of        differentiation of said cell to a cell having characteristics of        a dopaminergic neuron.

The developmental control gene in the above first description ofembodiments of the present invention may be selected from the groupconsisting of Math1, Hath1, Lhx8, Gbx1, Lhx6, IsL1, Dlx1/2, Mash andNurr1. The developmental control gene in the above second description ofembodiments of the present invention may be selected from the groupconsisting of Lhx8, Gbx1, Lhx6, IsL1, Dlx1/2, and Mash. Thedevelopmental control gene in the above third description of embodimentsof the present invention may be selected from the group consisting ofMath1 and Hath1. Finally, the developmental control gene in the abovefourth description of embodiments of the present invention may be Nurr1,Pitx3 (SEQ ID NO: 13) or other later-identified specific genes.

Also, it is appreciated that the present invention, particularly for thegenes Math1, Hath1, Lhx8, Gbx1, Lhx6, IsL1, Dlx1/2, and Mash, may beutilized in potent cells, that is, in cells that are considered to fallwithin the definitions of pluripotent, of multipotent, and of progenitorcells (i.e., more differentiated than multipotent yet capable of limitedself-renewal).

Based on the above examples and disclosure, in view of the knowledge andskill in the art, it also is appreciated that embodiments of the presentinvention also are used for any homeobox gene, so that a homeobox geneis transfected to a stem cell to effect a biasing of the stem cell todifferentiate to a desired end-stage cell, or to a cell havingcharacteristics of the end-stage cell. The stem cell may be apluripotent or a multipotent stem cell; alternatively inventionembodiments transfecting homeobox genes may be practiced with progenitorcells as described herein. Cells so biased by these genes following themethods of the present invention also are considered to fall within thescope of embodiments of the present invention.

EXAMPLE 6 Nkx2-5 Biases the Differentiation Toward the Development ofCardiac Cells

According to another embodiment, transfection with Nkx2-5 (SEQ ID NO:12) biases the differentiation toward the development of cardiac cells.See FIG. 17. Red=human specific Troponin I, Green=Human cells. Followingtransfection, multipotent stem cells were cocultured with ratcardiomyocytes that provide environmental signals to allow thetransfected cells to develop properly.

Further, and more generally, embodiments of the present invention may bepracticed by transfecting a stem or a progenitor cell with a nucleicacid sequence comprising a development control gene, so that thetransfecting is effective to bias the cell to differentiate to a desiredend-stage cell, or to a cell having characteristics of the end-stagecell.

Also, it is appreciated that the methods of the present invention may beapplied to the daughter cells of multipotent cells, which may have begunsome stages of differentiation but are still capable of being biased bytransfection of appropriate developmental control genes as describedherein, but by virtue of initiating differentiation (or being lessself-renewing) may by some opinions therefore not be considered to bemultipotent cells. For the purposes of this invention, such daughtercells, which may be found in culture with the multipotent stem cellsfrom which they arose, are termed “biasable progeny cells.”

It is appreciated that embodiments of the present invention also may bedefined and claimed with regard to the polypeptide or protein sequencesexpressed as a result of the transfections disclosed and discussedabove. For example, not to be limiting, the peptide sequences, disclosedas the translation sequences in the attached Sequence Listing pages, andtheir expression in a transfected cell, are used to identify and/orcharacterize a characteristic and/or result of embodiments of thepresent invention. Translation sequences are obtainable from therespective GenBank database data entries for cDNAs as described herein,and those database entries are incorporated by reference for suchinformation.

While a number of embodiments of the present invention have been shownand described herein in the present context, such embodiments areprovided by way of example only, and not of limitation. Numerousvariations, changes and substitutions will occur to those of skilled inthe art without materially departing from the invention herein. Forexample, the present invention need not be limited to best modedisclosed herein, since other applications can equally benefit from theteachings of the present invention. Also, in the claims,means-plus-function and step-plus-function clauses are intended to coverthe structures and acts, respectively, described herein as performingthe recited function and not only structural equivalents or actequivalents, but also equivalent structures or equivalent acts,respectively. Accordingly, all such modifications are intended to beincluded within the scope of this invention as defined in the followingclaims, in accordance with relevant law as to their interpretation.

What is claimed is:
 1. A method of biasing differentiation of a neural stem cell comprising introducing an expression construct comprising an Lhx8 and/or Gbx1 gene sequence into the neural stem cell, wherein expression of the Lhx8 and/or Gbx1 gene sequences are effective to bias the neural stem cell to a desired end-stage cell type, or to a presumptive end-stage cell having characteristics of the desired end-stage cell type, in vitro, wherein the desired end-stage cell type is a cholinergic neuron.
 2. An isolated cell produced by the method of claim
 1. 3. A method of biasing differentiation of a neural stem cell in vitro comprising: a. providing the neural stem cell; b. preparing a nucleic acid sequence comprising a promoter operatively linked to an expressible sequence that comprises an Lhx8 and/or Gbx1 gene sequence, the nucleic acid sequence comprising a transcription termination site; and c. transfecting said neural stem cell with said nucleic acid sequence, in vitro; wherein expression of the expressible sequence results in biasing the neural stem cell to a desired end-stage cell type, or to an presumptive end-stage cell having characteristics of the desired end-stage cell type, in vitro, wherein the desired end-stage cell type is cholinergic neuron.
 4. An isolated cell produced by the method of claim
 3. 5. A method of biasing differentiation of one or more cells in a population of cells comprising neural stem cells, comprising: a. providing the population of cells in a vessel; b. adding to the vessel one or more copies of a nucleic acid sequence comprising an Lhx8 and/or Gbx1 gene sequence under conditions to express said gene sequence; wherein expression of the gene sequence in one or more cells transfected, in vitro, with a copy of the nucleic acid sequence is effective to bias the one or more cells to a desired end-stage cell type, or to an presumptive end-stage cell having characteristics of the desired end-stage cell type, in vitro, wherein the desired end-stage cell type is a cholinergic neuron.
 6. The method of claim 5, the population of cells additionally comprising one or more biasable progeny cells.
 7. The method of claim 5, the neural stem cells comprising human neural stem cells.
 8. An isolated cell produced by the method of claim
 5. 9. A method of modifying a neural stem cell to bias differentiation of said neural stem cell toward a desired end-stage differentiated cell in vitro comprising the step of: introducing a nucleic acid sequence into said neural stem cell, in vitro, the nucleic acid sequence comprising a promoter operatively linked to a developmental control gene selected from the group consisting of an Lhx8 and Gbx1 gene sequence; wherein expression of the developmental biasing gene increases probability of said potent cell to differentiate into a desired end-stage differentiated cell, in vitro, wherein the desired end-stage cell type is cholinergic neuron. 